GlassScriptPhysician profile
Carol A Petruff
NPI 1083691794
$4,789.38
in general payments reported to CMS, 2019-2025
24 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $239 · 2021: $421 · 2022: $1,083 · 2023: $538 · 2024: $1,016 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,635 · Education: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.18 |
| Education | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,758.25 | 2019-2025 | |
| Celgene Corporation | $672.47 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $516.10 | 2019-2025 | Tremfya, Stelara, Remicade |
| Boston Scientific Corporation | $498.10 | 2019-2024 | Exalt Model D, Compliance Endokit |
| Takeda Pharmaceuticals U.S.A., INC. | $170.41 | 2019-2024 | Entyvio |
| Medtronic, INC. | $132.14 | 2022-2025 | Barrx |
| Fujifilm Healthcare Americas Corporation | $119.39 | 2025 | |
| Pfizer INC. | $106.51 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $103.96 | 2022-2023 | Rebyota |
| Ardelyx, INC. | $103.69 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $94.18 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $88.73 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $63.40 | 2023 | Ocaliva |
| Teleflex LLC | $55.17 | 2022 | |
| Qol Medical, LLC | $49.88 | 2025 | Sucraid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $43.64 | 2019 | |
| Ucb, INC. | $42.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.23 | 2019-2023 | Xifaxan |
| Madrigal Pharmaceuticals | $28.31 | 2024 | Resmetirom |
| Axonics, INC. | $26.82 | 2022 | |
| Lilly USA, LLC | $23.63 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.24 | 2023 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $18.25 | 2025 | Voquezna |
| Sandoz INC. | $14.74 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Petruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.